Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2004.030 | An One-Year Audit of Patients Attending A Multidisciplinary Out-patient Pain Centre | YEUNG Cheryl |
| 2006.205 | An Open Label International Multi-Center Phase 2 Activity and Safety Study of SU011248 in Patients with Advanced / Metastatic Gastric Cancer Progressing or Recurring After One Prior Chemotherapy | Prof. Yeo Winnie |
| 2006.230 | An Open Label International Multi-Center Phase 2 Activity and Safety Study of SU011248 in Patients with Unresectable Hepatocellular Carcinoma | YEO Winnie |
| 2011.048 | An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy | Dr Ho Wing Ming |
| 2014.668 | An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection | Prof. CHAN Henry Lik Yuen |
| 2006.249 | An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients with Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy | Prof. Tong Chun Yip Peter |
| 2007.036 | An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients with Persistent Microalbuminuria in Australia, New Zealand, and Hong Kong | Prof. Tong Chun Yip Peter |
| 2005.109 | An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies | Dr. Leung WY Nancy |
| 2005.279 | An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Indenix-Sponsored Telbivudine Studies | Prof. Chan Lik Yuen Henry |
| 2021.582 | An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation | Dr. LOONG Herbert Ho Fung |
| 2013.460 | An open label, multicentre, single-arm trial to assess the safety of afatinib for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) | Dr. LAM Kwok Chi |
| 2001.437 | An Open Label, Non-comparative Study to Assess the Efficacy and Safety of Oral Gemifloxacin 320mg, Once Daily for Seven Days, for the Treatment of Community-acquired Pneumonia of Suspected Pneumococcal Origin in Countries with a High Prevalence of Drug-resistant Respiratory Pathogens | Prof. Cheung Wai Lun Allen |
| 2010.547 | An Open Label, Non-Interventional, Observtional Study Following Implantation of the enVista Intraocular Lens | Prof Lam Shun Chiu Dennis |
| 2011.616 | An Open Label, Pharmacogenetic study of Bisoprolol Treatment in Patients with Uncontrolled Essential Hypertension | Professor Tomlinson Brian |
| 2013.117 | An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) | Dr. Hui Aric Josun |
| 2013.115 | An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) | Prof Chan Lik Yuen Henry |
| 2022.174 | AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) |
Prof. CHAN Stephen Lam 陳林 |
| 2014.409 | An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Prof. CHAN Anthony Tak Cheung |
| 2010.600 | An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects. | Professor Tomlinson Brian |
| 2007.038 | An Open Label, Randomized, Multi-Center, Parallel Group Study to Demonstrate Treatment of Anemia Using Intravenous Injections of RO0503821 in Patients with Chronic Kidney Disease Who are on Dialysis | Dr. Li KT Philip |
| 2003.190 | An Open Label, Randomized, Multicenter, Phase II Study to Determine Hemoglobin Dose Response, Safety and Pharmacokinetic Profile of Ro 50-3821 Given Subcutaneously Once Weekly or Once Every 3 Weeks to Anemic Patients with Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy | Prof. Mok S.K. Tony |
| 2005.415 | An Open Label, Randomized, Parallel Group, Multicentre, Phase III Study to Assess Efficacy, Safety and Tolerability of Gefitinib (IRESSA | Prof. Mok SK Tony |
| 2018.362 | An open uncontrolled trial of Imagery Rescripting for Depression |
Ms. LEE Sze Wai 李思慧 |
| 2004.371 | An Open-Label 7-Day Study to Determine the Influence of CYP2C19 Genotype on the Pharmacokinetics of RO2052349 in Patients with Type 2 Diabetes Mellitus in the Asia-Pacific Region | Prof. Brian Tomlinson |
| 2013.430 | AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | Dr. WONG Raymond Siu Ming |
| 2007.371 | An Open-Label Clinical Trial to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS_) Plus Entecavir (Baraclude) combination Therapy in HBeAg Positive Chronic Hepatitis B (CHB) Patients | Prof. Sung JY Joseph |
| 2006.367 | An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer | Dr. Ho Wing Ming |
| 2008.382 | An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures | Dr Kwan Patrick |
| 2003.293 | An Open-Label Extension Study to Assess the Safety and Tolerability of a 25mg Dose of SCH 420814 as Monotherapy in Subjects with Early Parkinson | Prof. Wong Ka Sing Lawrence |
| 2011.599 | An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn | Dr Ng Siew Chien |
| 2021.535 | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors |
Dr. LEUNG Wing Kwan 梁永堃 |
| 2019.481 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Dr. WONG Raymond Siu Ming |
| 2021.567 | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2002.411 | An Open-Label Extension Trial to Assess The Safety of Galantamine HBr in the Treatment of Vascular Dementia Revised : cre-2002.216-t, cre-2002.124-t | Prof. Wong Ka Sing Lawrence |
| 2005.300 | An Open-Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80mg + Hydrochlorothiazide 25mg tablets Alone or in Combination with Other Antihypertensive Medications in Patients with Hypertension | Prof. Kong Pik Shan Alice |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
| 2011.028 | An open-label multi-center study of erlotinib (Tarceva®) as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutations | Prof. MOK Tony Shu Kam |
| 2010.158 | An Open-Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures | Dr. Kwan Patrick |
| 2005.197 | An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL_/CAELYX_ and YONDELIS | Prof. Yeo Winnie |
| 2007.247 | An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women with Advanced or Metastatic Breast Cancer | Prof. Yeo Winnie |
| 2024.724 | An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma as Second Line Therapy |
Prof. CHAN Stephen Lam 陳林 |
| 2023.312 | An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B | Prof. WONG Grace |
| 2007.241 | An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years | Prof. Hui SC David |
| 2016.165 | An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma |
Dr. LOONG Herbert 龍浩鋒 |
| 2010.457 | An Open-label Phase Ii Study of TK1258 as Neo-adjuvant Therapy in Patient with Muscle-invasive Bladder Cancer | Dr Chan Shu Yin Eddie |
| 2002.394 | An Open-Label Phase IIa Trial of Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients with Advanced Local or Metastatic Gastric Cancer | Prof. Yeo Winnie |
| 2018.444 | An open-label pilot study of fecal microbiota transplant (FMT) to induce weight loss in obese subjects |
Prof. NG Siew Chien 黃秀娟教授 |
| 2007.242 | An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects with Schizophrenia | Dr. Chung Wai Sau Dicky |
| 2021.134 | An open-label randomized controlled trial on convalescent plasma for treatment of severe COVID-19 infection |
Dr. LUI Grace C.Y. 雷頌恩 |
| 2015.607 | An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer |
Prof. MOK Tony Shu Kam 莫樹錦 |
Page 57 of 262.